Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis | Zendy

Hanneke M. J. Nijland | Zendy; Rovina Ruslami | Zendy; A. J. Suroto | Zendy; David M. Burger | Zendy; Bachti Alisjahbana | Zendy; Reinout van Crevel | Zendy; Rob E. Aarnoutse | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Author(s) -

Hanneke M. J. Nijland,

Rovina Ruslami,

A. J. Suroto,

David M. Burger,

Bachti Alisjahbana,

Reinout van Crevel,

Rob E. Aarnoutse

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/521894

Subject(s) - moxifloxacin , rifampicin , medicine , pharmacokinetics , isoniazid , confidence interval , bioequivalence , pharmacology , antibacterial agent , area under the curve , tuberculosis , antibiotics , microbiology and biotechnology , pathology , biology

The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows promising results and may be combined with rifampicin to shorten the duration of TB treatment. Rifampicin induces the phase II metabolic enzymes that are involved in the biotransformation of moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin should be investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research